Další formáty:
BibTeX
LaTeX
RIS
@article{1204362,
author = {Vaclavik, Jan and Sedlak, Richard and Jarkovský, Jiří and Kocianova, Eva and Taborsky, Milos},
article_location = {Olomouc},
article_number = {3},
doi = {http://dx.doi.org/10.5507/bp.2012.105},
keywords = {Age; Blood pressure; Resistant hypertension; Sex; Spironolactone},
language = {eng},
issn = {1213-8118},
journal = {Biomedical Papers of the Faculty of Medicine and Dentistry of Palacký University, Olomouc, Czech Republic},
title = {Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: Insights from the aspirant trial},
volume = {158},
year = {2014}
}
TY - JOUR
ID - 1204362
AU - Vaclavik, Jan - Sedlak, Richard - Jarkovský, Jiří - Kocianova, Eva - Taborsky, Milos
PY - 2014
TI - Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: Insights from the aspirant trial
JF - Biomedical Papers of the Faculty of Medicine and Dentistry of Palacký University, Olomouc, Czech Republic
VL - 158
IS - 3
SP - 384-390
EP - 384-390
PB - Palacký University
SN - 12138118
KW - Age
KW - Blood pressure
KW - Resistant hypertension
KW - Sex
KW - Spironolactone
N2 - Methods. Patients with an office systolic blood pressure (BP) >140 mmHg or diastolic BP >90 mmHg, despite treatment with at least 3 antihypertensive drugs including a diuretic, were randomly assigned to receive spironolactone or a placebo for 8 weeks in a double-blind, placebo-controlled, multicentre trial (ASPIRANT). Background. There are currently limited data on whether the effect of spironolactone in patients with resistant arterial hypertension depends on age and sex. Results. Analyses were done on 55 patients treated with spironolactone and 56 patients treated with placebo. Significant reductions of office systolic BP (-8.9 +/- 6.7 mmHg, P=0.012), 24-h ABPM systolic BP (-7.9 +/- 7.2 mmHg, P=0.032) and ABPM day-time systolic BP (-7.5 +/- 7.1 mmHg) after 8 weeks of spironolactone treatment, compared to placebo, were only observed in patients with a median age 62 years, and is effective to a similar extent in men and women.
ER -
VACLAVIK, Jan, Richard SEDLAK, Jiří JARKOVSKÝ, Eva KOCIANOVA a Milos TABORSKY. Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: Insights from the aspirant trial. \textit{Biomedical Papers of the Faculty of Medicine and Dentistry of Palacký University, Olomouc, Czech Republic}. Olomouc: Palacký University, 2014, roč.~158, č.~3, s.~384-390. ISSN~1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2012.105.
|
